Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELITE PHARMACEUTICALS INC /NV/ELTP · Entity 5936 | Director | November 22, 2023 | November 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELITE PHARMACEUTICALS INC /NV/
Report date November 22, 2023 · Filed November 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,187,020 |
Reported balance
After 2023-11-22 transaction · row 1
1 source rowRow 1 · 2023-11-22 · Grant · Acquired 547,657 · Balance 3,187,020 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 22, 2023 Filed Nov 28, 2023 00:05 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 547,657 | $0.04 | $19,989.48 |
DisclosureSEC source: 0001324222-23-000003 · primary_doc.xml · nonDerivative · entry 1 WHITNELL JEFFREY A · CIK 0001126562 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,187,020 Read SEC document |
| August 28, 2022 Filed Aug 29, 2022 17:49 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 459,536 | $0.04 | $19,989.82 |
DisclosureSEC source: 0001324222-22-000003 · primary_doc.xml · nonDerivative · entry 1 WHITNELL JEFFREY A · CIK 0001126562 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,639,363 Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 22:36 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 295,570 | $0.07 | $20,010.09 |
DisclosureSEC source: 0001324222-21-000003 · primary_doc.xml · nonDerivative · entry 1 WHITNELL JEFFREY A · CIK 0001126562 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,179,827 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 18:15 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 516,781 | $0.09 | $45,011.63 |
DisclosureSEC source: 0001324222-20-000003 · primary_doc.xml · nonDerivative · entry 1 WHITNELL JEFFREY A · CIK 0001126562 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,884,257 Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 21:53 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 161,374 | $0.12 | $19,994.24 |
DisclosureSEC source: 0001053369-18-000003 · primary_doc.xml · nonDerivative · entry 1 WHITNELL JEFFREY A · CIK 0001126562 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,367,476 Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:26 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 88,679 | $0.23 | $19,997.11 |
DisclosureSEC source: 0001053369-17-000003 · primary_doc.xml · nonDerivative · entry 1 WHITNELL JEFFREY A · CIK 0001126562 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,206,102 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.